Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 1/20 | 0.53 |
| ▸ | MDM4 | O15151 | 3/20 | 0.52 |
| ▸ | TP53 | P04637 | 3/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.47 |
| ▸ | MDM2 | Q00987 | 4/20 | 0.47 |
| ▸ | CASP3 | P42574 | 2/20 | 0.47 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL119512 | 1.00 | FPR2 (0.53) | FPR2MDM4TP53PTPN1MDM2 | |
| SCHEMBL29402299 | 1.00 | FPR2 (0.53) | FPR2MDM4TP53PTPN1MDM2 | |
| SCHEMBL29907959 | 1.00 | FPR2 (0.53) | FPR2MDM4TP53PTPN1MDM2 | |
| SCHEMBL3366913 | 1.00 | FPR2 (0.53) | FPR2MDM4TP53PTPN1MDM2 | |
| SCHEMBL31369603 | 0.92 | MDM4 (0.52) | MDM4TP53PTPN1MDM2CASP3 | |
| SCHEMBL27101546 | 0.92 | CA2 (0.51) | MDM4TP53PTPN1MDM2CASP3 | |
| SCHEMBL30898985 | 0.92 | CA2 (0.51) | MDM4TP53PTPN1MDM2CASP3 | |
| SCHEMBL2578833 | 0.92 | CA2 (0.51) | MDM4TP53PTPN1MDM2CASP3 | |
| SCHEMBL29400332 | 0.92 | CA2 (0.51) | MDM4TP53PTPN1MDM2CASP3 | |
| SCHEMBL16095683 | 0.91 | MDM2 (0.51) | FPR2MDM4TP53PTPN1MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3727462-B1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EPHA2 | BICYCLERD LTD (GB) | 2025-11-05 | — | — | EP | disclosed |
| US-20250255975-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR MT1-MMP | Bicyclerd Limited (GB) | 2025-08-14 | — | — | US | disclosed |
| US-20250230191-A1 | PEPTIDE LIGANDS FOR BINDING TO MT1-MMP | BICYCLETX LIMITED (GB) | 2025-07-17 | — | — | US | disclosed |
| EP-3727461-B1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EPHA2 | BICYCLETX LTD (GB) | 2025-07-09 | — | — | EP | disclosed |
| EP-4582436-A2 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EPHA2 | BicycleTX Limited (GB) | 2025-07-09 | — | — | EP | disclosed |
| US-12318454-B2 | Bicyclic peptide ligands specific for MT1-MMP | Bicyclerd Limited (GB) | 2025-06-03 | — | — | US | disclosed |
| EP-3452096-B1 | BICYCLIC PEPTIDE-TOXIN CONJUGATES SPECIFIC FOR MT1-MMP | BICYCLERD LTD (GB) | 2025-01-29 | — | — | EP | disclosed |
| US-20240082410-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR MT1-MMP | Bicyclerd Limited (GB) | 2024-03-14 | — | — | US | disclosed |
| US-20230340020-A1 | PEPTIDE LIGANDS FOR BINDING TO MT1-MMP | BICYCLETX LIMITED (GB) | 2023-10-26 | — | — | US | disclosed |
| US-11672868-B2 | Bicyclic peptide ligands specific for MT1-MMP | Bicyclerd Limited (GB) | 2023-06-13 | — | — | US | disclosed |
| US-6936586-B1 | Synthetic IL-10 analogues | STEENO RESEARCH GROUP A/S (DK) | 2005-08-30 | — | — | US | disclosed |
| US-20050004131-A1 | Substituted hexahydropyrazino (1,2-a) pyrimidine-4,7-dione derivatives, processes for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-01-06 | — | — | US | disclosed |
| WO-2004072076-A1 | SUBSTITUTED HEXAHYDROPYRAZINO(1,2-A)PYRIMIDIN-4,7-DION DERIVATIVES, METHOD FOR THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-08-26 | — | — | WO | disclosed |
| US-20040014676-A1 | SRC kinase inhibitors useful for treating osteoporosis | ARIAD PHARMACEUTICALS INC. | 2004-01-22 | — | — | US | disclosed |
| US-6548637-B1 | Endomorphine analog analgesics | SEPRACOR, INC. | 2003-04-15 | — | — | US | disclosed |
| EP-1296961-A1 | 1,4-DIAZEPAN-2,5-DIONE DERIVATIVES AND THEIR USE AS NK-1 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-04-02 | — | — | EP | disclosed |
| US-6452001-B2 | 1,4-DIAZEPINE-2-ONE DERIVATIVES AS NEUROKININ ANTAGONIST | HOFFMANN-LA ROCHE INC. | 2002-09-17 | — | — | US | disclosed |
| US-20020010174-A1 | Diazapane derivatives useful as antagonists of neurokinin 1 receptor and methods for their formation | F. HOFFMANN-LA ROCHE AG (CH) | 2002-01-24 | — | — | US | disclosed |
| WO-2001090083-A1 | 1,4-DIAZEPAN-2,5-DIONE DERIVATIVES AND THEIR USE AS NK-1 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-11-29 | — | — | WO | disclosed |
| WO-1999065932-A1 | TETRAPEPTIDES, ANALOGS AND PEPTIDOMIMETICS WHICH BIND SELECTIVELY MAMMALIAN OPIOID RECEPTORS | SEPRACOR, INC. (US) | 1999-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250230191-A1 | PEPTIDE LIGANDS FOR BINDING TO MT1-MMP | MMP11, MMP3, ANPEP | FPR2 998/4885MDM4 3415/4885TP53 3318/4885 |
| US-20230340020-A1 | PEPTIDE LIGANDS FOR BINDING TO MT1-MMP | MMP11, MMP3, ANPEP | FPR2 922/4885MDM4 3392/4885TP53 3131/4885 |
| US-20250255975-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR MT1-MMP | MMEL1, MMP3, TIMP3 | FPR2 797/4885MDM4 2089/4885TP53 826/4885 |
| US-20040014676-A1 | SRC kinase inhibitors useful for treating osteoporosis | SRC, CTTN, YES1 | FPR2 1964/4885MDM4 2715/4885TP53 1918/4885 |
| US-12318454-B2 | Bicyclic peptide ligands specific for MT1-MMP | MMEL1, MMP3, TIMP3 | FPR2 797/4885MDM4 2089/4885TP53 826/4885 |
| US-11672868-B2 | Bicyclic peptide ligands specific for MT1-MMP | MMEL1, MMP3, TIMP3 | FPR2 797/4885MDM4 2089/4885TP53 826/4885 |
| US-20240082410-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR MT1-MMP | MMEL1, MMP3, TIMP3 | FPR2 797/4885MDM4 2089/4885TP53 826/4885 |
| US-20050004131-A1 | Substituted hexahydropyrazino (1,2-a) pyrimidine-4,7-dione derivatives, processes for their preparation and their use as medicaments | DPYD, TYMP, G6PD | FPR2 1111/4885MDM4 3004/4885TP53 3157/4885 |
| US-20020010174-A1 | Diazapane derivatives useful as antagonists of neurokinin 1 receptor and methods for their formation | BDKRB2, NPSR1, BDKRB1 | FPR2 410/4885MDM4 4759/4885TP53 4674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.